Innovative Blood Test Aids Early Detection of Breast Cancer
|
By LabMedica International staff writers Posted on 25 Nov 2019 |
|
Image: A simple blood test could diagnose breast cancer up to five years before symptoms occur. The presence of autoantibodies, that compliment tumor-associated antigens, help to diagnose breast cancer earlier (Photo courtesy of Oncology Central).
A blood test is being developed that could help detect breast cancer five years before any symptoms become apparent. This method would also be less uncomfortable and more cost effective than traditional mammograms.
Early diagnosis of cancer is paramount to improved survival by enabling treatment prior to cancer spreading, when tumors should be both surgically removable and curable. Autoantibodies against numbers of tumor-associated antigens (TAAs) have been shown to be relevant tumor biomarkers and can be detected up to five years before the tumor is overt clinically.
A team of scientists working at the University of Nottingham (Nottingham, UK) first developed panels of tumor-associated antigens (TAAs) specific to breast cancer. This allowed them to screen for the presence of autoantigens in blood that are associated with a response to breast cancer-specific TAAs. In a pilot study, they screened 180 breast cancer matched control samples for the presence of autoantibodies against 67 TAAs which have already been shown to involve in breast cancer pathology. Optimized Protein microarray technology was applied for this study. They used specialized screening methods to look for autoantibodies generated against 40 TAAs they already knew were associated with blood cancer and 27 TAAs that were not known to have a link with this type of cancer.
In total, the team developed three panels of TAAs that allowed them to screen for autoantibodies that respond to them, and, the investigators noted, the more TAAs present in a panel, the more accurate the blood test results. The panel featuring five TAAs facilitated the correct detection of breast cancer in 29% of the samples from people with breast cancer. It also confirmed the lack of breast cancer in 84% of the samples from the control group. The panel featuring seven TAAs allowed for the correct detection of breast cancer in 35% of the samples collected from people with cancer, and it confirmed the lack of cancer in 79% of the samples from people without cancer. The panel containing nine TAAs led to the detection of cancer in 37% of the samples from individuals with breast cancer, and it confirmed the lack of cancer in 79% of the control samples.
Daniyah Alfattani, a PhD student and co-author of the study, said, “The results of our study showed that breast cancer does induce autoantibodies against panels of specific TAAs. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood. This innovative blood test could help specialists detect the presence of breast cancer up to five years before any visible symptoms occur.” The study was presented at the 2019 National Cancer Research Institute conference held November 3-5, 2019 in Glasgow, UK.
Related Links:
University of Nottingham
Early diagnosis of cancer is paramount to improved survival by enabling treatment prior to cancer spreading, when tumors should be both surgically removable and curable. Autoantibodies against numbers of tumor-associated antigens (TAAs) have been shown to be relevant tumor biomarkers and can be detected up to five years before the tumor is overt clinically.
A team of scientists working at the University of Nottingham (Nottingham, UK) first developed panels of tumor-associated antigens (TAAs) specific to breast cancer. This allowed them to screen for the presence of autoantigens in blood that are associated with a response to breast cancer-specific TAAs. In a pilot study, they screened 180 breast cancer matched control samples for the presence of autoantibodies against 67 TAAs which have already been shown to involve in breast cancer pathology. Optimized Protein microarray technology was applied for this study. They used specialized screening methods to look for autoantibodies generated against 40 TAAs they already knew were associated with blood cancer and 27 TAAs that were not known to have a link with this type of cancer.
In total, the team developed three panels of TAAs that allowed them to screen for autoantibodies that respond to them, and, the investigators noted, the more TAAs present in a panel, the more accurate the blood test results. The panel featuring five TAAs facilitated the correct detection of breast cancer in 29% of the samples from people with breast cancer. It also confirmed the lack of breast cancer in 84% of the samples from the control group. The panel featuring seven TAAs allowed for the correct detection of breast cancer in 35% of the samples collected from people with cancer, and it confirmed the lack of cancer in 79% of the samples from people without cancer. The panel containing nine TAAs led to the detection of cancer in 37% of the samples from individuals with breast cancer, and it confirmed the lack of cancer in 79% of the control samples.
Daniyah Alfattani, a PhD student and co-author of the study, said, “The results of our study showed that breast cancer does induce autoantibodies against panels of specific TAAs. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood. This innovative blood test could help specialists detect the presence of breast cancer up to five years before any visible symptoms occur.” The study was presented at the 2019 National Cancer Research Institute conference held November 3-5, 2019 in Glasgow, UK.
Related Links:
University of Nottingham
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Automated MALDI-TOF MS System
EXS 3000
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Latest Immunology News
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
Channels
Clinical Chemistry
view channel
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
People with diabetes often need to measure their blood glucose multiple times a day, most commonly through finger-prick blood tests or implanted sensors. These methods can be painful, inconvenient, and... Read more
Molecular Diagnostics
view channel
Neuron-Derived Extracellular Vesicles Could Improve Alzheimer’s Diagnosis
Alzheimer’s disease is becoming increasingly common as global populations age, yet effective treatments for advanced stages remain limited. Early detection is therefore critical, but current diagnostic... Read more
Sample Prep Instrument to Empower Decentralized PCR Testing for Tuberculosis
Tuberculosis remains the deadliest infectious disease worldwide despite being both treatable and curable when diagnosed early. A major barrier to timely diagnosis is that PCR-based TB testing is still... Read more
Endometriosis Blood Test Could Replace Invasive Laparoscopic Diagnosis
Endometriosis affects an estimated 1 in 10 women globally, yet diagnosis can take 7 to 10 years on average due to the invasive nature of laparoscopy and lack of accurate, non-invasive tests.... Read more
World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device
Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreMicrobiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more
Technology
view channel
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more
Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
Glioblastoma is one of the most aggressive and fatal brain cancers, with most patients surviving less than two years after diagnosis. Treatment is particularly challenging because the tumor infiltrates... Read more
Industry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more
